Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Restricted Cash

The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):

	December 31,
	2021		2020
Cash and cash equivalents	$	12,586	$	10,604
Restricted cash		—		7,508
Total cash and restricted cash presented in the consolidated statements of cash flows	$	12,586	$	18,112

Accrued Warranty Costs Activity

The activity in the warranty accrual during the years ended December 31, 2021 and 2020 is summarized as follows (in thousands):

	December 31,
	2021			2020
Balance, beginning of year	$	113		$	232
Additions		71			67
Expirations and claims satisfied		(105	)		(186	)
Total		79			113
Less current portion within accrued expenses and other current liabilities		(59	)		(87	)
Balance within deferred revenues and other liabilities	$	20		$	26

Disaggregation of Revenue

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2021		2020
Dermatology recurring procedures	$	22,528	$	17,409
Dermatology procedures equipment		7,449		5,681
Total net revenues	$	29,977	$	23,090

Future Undiscounted Fixed Treatment Code Payments

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from dermatology recurring procedures (in thousands):

Years ending December 31:
2022	$	1,680
2023		1,624
2024		1,303
2025		530
2026		4
	$	5,141

Antidilutive Securities Excluded from Computation of Earnings (Loss) Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2021		2020
Unvested restricted stock units		90,540		—
Stock options		3,938,613		5,292,888
Common stock warrants		373,626		19,812
		4,402,779		5,312,700